Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model

IntroductionWe evaluated the cost-effectiveness of South Korea's planned annual coronavirus disease 2019 (COVID-19) booster campaign scheduled for October 2023.Materials and methodsAn age-structured mathematical model was used to analyze the public impacts and cost-effectiveness of vaccination across three vaccination strategies: uniform allocation and prioritizing those over 65 or those over 50 years old. We calculated the incremental cost per quality-adjusted life year (QALY) from both healthcare and societal perspectives. The maximum vaccine cost for cost-effectiveness was also identified.ResultsOur analysis highlights the cost-effectiveness of South Korea's annual COVID-19 vaccination program in mitigating health and economic impacts. The most cost-effective strategy is uniform vaccine allocation, offering the lowest incremental cost-effectiveness ratio (ICER) at US$ 25,787/QALY. However, with a relatively high attack rate, the strategy prioritizing individuals over 65 years emerges as more cost-effective, lowering the ICER to US$ 13,785/QALY. Prioritizing those over 50 was less cost-effective. All strategies were cost-saving from a societal perspective, with cost-effectiveness being more sensitive to vaccine price than to its effectiveness.DiscussionOur results imply a potential strategy shift in current vaccination plan, with uniform vaccine distribution being more cost-effective than prioritizing older adults. Early estimation of viral transmissibility and vaccine effectiveness is crucial in determining the most cost-effective vaccine allocation approach.